Assessment of Potential Cross-Reactivity of Human Endogenous Matrix Metalloproteinases with Collagenase Clostridium histolyticum Antibodies in Human Sera Obtained from Patients with Dupuytren's Contracture

Edkins, Thomas J.; Koller-Eichhorn, Roland; Alhadeff, Jack A.; Mayer, U.; Faust, Heinrich; Tito, Benjamin J. Del

doi:10.1128/cvi.00018-12

Cited by 14 publications

(6 citation statements)

References 19 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous clinical, toxicology, and immunology studies suggested safety with complete CCH bottle injection (Badalamente et al, 2002;Edkins et al, 2012). Safety with injection greater than 0.58 mg CCH also supported with preliminary unpublished and exploratory published multi-cord studies, injecting two concurrent cords, each with 0.58 mg of CCH (Coleman et al, 2012).…”

Section: Introductionmentioning

confidence: 77%

Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique

Verheyden

2014

J Hand Surg Eur Vol

View full text Add to dashboard Cite

Collagenase clostridium histolyticum is the first and only United States Food and Drug Association approved nonsurgical treatment for patients with a palpable Dupuytren's contracture cord. However, the Food and Drug Association has only approved injection of 0.58 mg of this enzyme into one palpable Dupuytren's contracture cord at a time. This review reports on the early outcome of 144 patients treated with the entire bottle of enzyme, approximately 0.78 mg, along with use of a novel slow intracord multi-cord technique. Use of 0.78 mg of enzyme, with the slow intracord multi-cord technique is safe and allows one to inject multiple Dupuytren's contracture cords at one setting. Correction at metacarpophalangeal and proximal interphalangeal joints, taken individually, are comparable with the Collagenase Option for the Reduction of Dupuytren's studies at 43° and 33°, respectively, however due to the multi-cord injection, we achieved 94° average immediate and 76° average final combined metacarpophalangeal and proximal interphalangeal contracture releases per bottle of enzyme. Implementation of the slow intracord multi-cord technique has the potential to improve current treatment for Dupuytren's contracture with resultant significant healthcare savings.

show abstract

Section: Introductionmentioning

confidence: 77%

Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique

Verheyden

2014

J Hand Surg Eur Vol

View full text Add to dashboard Cite

show abstract

“…32,35,43 This crude collagenase is in fact a mixture of several enzymes, including type I and type II collagenase. 73 Because of the functional relation of these two enzymes to MMPs, 74 CHC is likely to act as model enzyme for wound proteases. We analyzed this feature with soluble eADF4(C16), which was incubated both with CHC and with MMP-2, -8, -9, and -13 and PMN elastase in order to evaluate the extent of conclusions to be drawn from using CHC as a model enzyme.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

Enzymatic Degradation of Films, Particles, and Nonwoven Meshes Made of a Recombinant Spider Silk Protein

Müller-Herrmann

Scheibel

2015

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The performance of biomaterials in vivo is largely influenced by their stability and the rate and extent to which they degrade. Materials for tissue engineering applications, for example, have to be mechanically stable to support cell adhesion and proliferation without collapsing. On the other hand they need to be replaced gradually by native extracellular matrix and have to be (slowly) biodegradable. Therefore, it is of critical importance to be able to tune the degradation behavior of a biomaterial. Recombinantly produced spider silk proteins have been shown to be versatile biopolymers for medical applications. They can be processed into a variety of morphologies, and by chemical or genetic modification the properties can be adjusted to specific demands. Furthermore, in vivo experiments confirmed the lack of immunological reactions toward certain spider silks. In this study the degradation behavior of the recombinant spider silk protein eADF4(C16) in solution as well as processed into particles, films and nonwoven meshes was analyzed, and the impact of crosslinking of the scaffolds was assessed thereon. In addition to two bacterial proteolytic model enzymes, protease type XIV from Streptomyces griseus (PXIV) and collagenase type IA from Clostridium histolyticum (CHC) used in all experiments, several recombinant human matrix metalloproteinases (MMPs) and one elastase were used in studying degradation of soluble eADF4(C16). For soluble eADF4(C16) all degradation kinetics were similar. In case of eADF4(C16) scaffolds significant differences were observable between PXIV and CHC. All scaffolds were more stable toward proteolytic degradation in the presence of CHC than in the presence of PXIV. Further, particles were degraded significantly faster than films, and nonwoven meshes showed the highest proteolytic stability. Chemical cross-linking of the scaffolds led to a decrease in both degradation rate and extent.

show abstract

“…Furthermore, with the sequence identity well below 40% with those from organisms like Brucella spp., Chalmydia spp., and C. burnetii, Pap31 is unlikely to show cross-reactivity with antibodies against those organisms. 28 In addition, our test is more likely to have a higher sensitivity than the IFA for detecting antibodies. While the ELISA plates were coated with a higher amount of a single specific immunoreactive antigen, the IFA was coated with the whole cell antigen, which also contained non-immunogenic proteins.…”

Section: Discussionmentioning

confidence: 99%

An Evaluation Study of Enzyme-Linked Immunosorbent Assay (ELISA) Using Recombinant Protein Pap31 for Detection of Antibody against Bartonella bacilliformis Infection among the Peruvian Population

Angkasekwinai¹,

Atkins

Romero

et al. 2014

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Reliable laboratory testing is of great importance to detect Bartonella bacilliformis infection. We evaluated the sensitivity and specificity of the enzyme-linked immunosorbent assay (ELISA) using recombinant protein Pap31 (rPap31) for the detection of antibodies against B. bacilliformis as compared with immunofluorescent assay (IFA). Of the 302 sera collected between 1997 and 2000 among an at-risk Peruvian population, 103 and 34 samples tested positive for IFA-immunoglobulin G (IgG) and IFA-IgM, respectively. By using Youden's index, the cutoff values of ELISA-IgG at 0.915 gave a sensitivity of 84.5% and specificity of 94%. The cutoff values of ELISA-IgM at 0.634 gave a sensitivity of 88.2% and specificity of 85.1%. Using latent class analysis, estimates of sensitivity and specificity of almost all the assays were slightly higher than those of a conventional method of calculation. The test is proved beneficial for discriminating between infected and non-infected individuals with the advantage of low-cost and high-throughput capability.

show abstract

Assessment of Potential Cross-Reactivity of Human Endogenous Matrix Metalloproteinases with Collagenase Clostridium histolyticum Antibodies in Human Sera Obtained from Patients with Dupuytren's Contracture

Cited by 14 publications

References 19 publications

Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique

Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique

Enzymatic Degradation of Films, Particles, and Nonwoven Meshes Made of a Recombinant Spider Silk Protein

An Evaluation Study of Enzyme-Linked Immunosorbent Assay (ELISA) Using Recombinant Protein Pap31 for Detection of Antibody against Bartonella bacilliformis Infection among the Peruvian Population

Contact Info

Product

Resources

About